M&A Deal Summary

Opko Acquires Pharma Genexx S.A.

On October 2, 2009, Opko acquired medical products company Pharma Genexx S.A. for 16M USD

Acquisition Highlights
  • This is Opko’s 3rd transaction in the Medical Products sector.
  • This is Opko’s 5th largest (disclosed) transaction.
  • This is Opko’s 1st transaction in Chile.

M&A Deal Summary
Date 2009-10-02
Target Pharma Genexx S.A.
Sector Medical Products
Buyer(s) Opko
Deal Type Add-on Acquisition
Deal Value 16M USD

Target

Pharma Genexx S.A.

Santiago, Chile
Pharma Genexx S.A. is a privately-held Chilean pharmaceutical company engaged in the representation, importation, commercialization and distribution of pharmaceutical products.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Opko

Miami, Florida, United States
Category Company
Founded 1991
Sector Life Science
Employees3,930
Revenue 863M USD (2023)
DESCRIPTION
Opko's corporate headquarters in Miami, Florida.
Opko's corporate headquarters in Miami, Florida.

Opko is a diversified healthcare company with a focus on establishing leading positions in significant and rapidly growing medical markets. Opko's operations are divided into diagnostics and pharmaceuticals, each with specialized products and services aimed at improving patient care and outcomes. Opko was founded in 1991 and is based in Miami, Florida.

DEAL STATS #
Overall 3 of 20
Sector (Medical Products) 3 of 10
Type (Add-on Acquisition) 3 of 18
Country (Chile) 1 of 2
Year (2009) 1 of 2
Size (of disclosed) 5 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-05-07 Vidus Ocular

United States

Vidus Ocular, Inc. is a developer of Aquashunt(TM), an innovative shunt to treat glaucoma, the second cause of blindness. Aquashunt is an implantable physiologic device that is designed to address the shortcomings of current glaucoma treatments.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-11-11 OPKO - Rolapitant

United States

OPKO - Rolapitant is a neurokinin-1 (NK-1) receptor antagonist, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.

Buy -
Mergr

Product

Company

Legal